 |
|
|
|
|
|
 Title: |
US5229137:
Methods and pharmaceutical compositions for treating episodic heartburn
[ Derwent Title ]
|
| Country: |
US United States of America
|
| |
| Inventor: |
Wolfe, M. Michael; Newton, MA
|
| Assignee: |
Brigham and Women's Hospital, Inc., Boston, MA
other patents from BRIGHAM AND WOMEN'S HOSPITAL (75590) (approx. 328)
News, Profiles, Stocks and More about this company
|
| Published / Filed: |
1993-07-20
/ 1992-05-06
|
| Application Number: |
US1992000879662
|
| IPC Code: |
Advanced:
A61K 33/00;
A61K 33/08;
A61K 33/10;
IPC-7:
A61K 31/34;
A61K 31/415;
A61K 31/425;
A61K 31/695;
A61K 33/00;
A61K 33/08;
A61K 33/10;
|
| ECLA Code: |
A61K33/00; A61K33/08; A61K33/10;
|
| U.S. Class: |
Current:
424/687;
424/690;
424/692;
424/717;
514/063;
514/365;
514/370;
514/400;
514/461;
514/819;
514/820;
Original:
424/687;
424/690;
424/692;
424/717;
514/063;
514/365;
514/370;
514/400;
514/461;
514/819;
514/820;
|
| Field of Search: |
424/688,687,682,690,692,717
514/400,461,820,63,365,370,819
|
| Priority Number: |
| 1992-05-06 |
US1992000879662 |
|
| Abstract: |
Pharmaceutical medications and methods are disclosed for providing instant and sustained relief from pain or symptoms associated with episodic heartburn in humans. The medications consist essentially of antacids and histamine H2-receptor antagonists, and may be administered on an as-needed basis in liquid or solid dosage forms. Typical antacids which may be used in combination with the histamine H2-receptor antagonist are conventional antacids which are well known and widely used in the treatment of excess acid related gastrointestinal dysfunctions. Exemplary of typical antacids include, sodium bicarbonate, calcium carbonate, magnesium hydroxide and aluminum hydroxide, as well as commercially available high potency, flavored antacids. Histamine H2-receptor antagonists which may be used in combination include those conventionally used in the treatment of peptic ulcers, such as, for example, cimetidine, ranitidine, famotidine and nizatidine. In carrying out the methods, an antacid and histamine H2-receptor antagonist may be administered together as a single unitary dose in the form of a liquid or solid, or administered together, but separately as either liquids or solids or a combination thereof. The oral medications when formulated as a single unitary dose may include other additives, such as, for example, antiflatulents, flavorings, sweeteners and the like.
|
| Attorney, Agent or Firm: |
Ruden, Barnett, McClosky, Smith, Schuster & Russell ;
|
| Primary / Asst. Examiners: |
Waddell, Frederick E.; Henley, III, Raymond J.
|
| INPADOC Legal Status: |
Show legal status actions
Family Legal Status Report
|
| Family: |
Show 3 known family members
|
First Claim:
Show all 27 claims |
Having described my invention, I claim:
1. A method of providing immediate and sustained relief from pain, discomfort and/or symptoms associated with episodic heartburn in a human, said method comprising:
- orally administering to a human together or substantially together an antacid in an amount effective to substantially neutralize gastric acid and a histamine H2 -receptor antagonist in an amount effective to substantially inhibit or block gastric acid secretion for providing the human with immediate and sustained relief from pain, discomfort and/or symptoms associated with episodic heartburn, the immediate and sustained relief provided lasting longer in duration than when the human is orally treated with only the antacid and the immediate and sustained relief provided being faster than and lasting at least about as long in duration as when the human is orally treated with only the histamine H2 -receptor antagonist.
|
| Background / Summary: |
Show background / summary
|
| Drawing Descriptions: |
Show drawing descriptions
|
| Description: |
Show description
|
| Forward References: |
Show 38 U.S. patent(s) that reference this one
|
|
|
|
|
|
|
| Foreign References: |
None
|
| Other References: |
Avery's Drug Treatment, 3rd edition (1987) pp. 742-743.
Steinberg, W. M. et al.: N Engl J Med, 307(7):400-404 (Aug. 12, 1982).
(5 pages)
Mihaly, G. W. et al.: Br Med J, 285:998-999 (Oct. 9, 1982).
(2 pages)
Harvey, Stewart C., "Chapter 42: Gastric Antacids, Miscellaneous Drugs for the Treatment of Peptic Ulcers, Digestions, and Bileacids" Goodman & Gilman's The Pharmacological Basis of Therapeutics, 7th Ed., McMillan (1985).
Douglas, W., "Chaper 26: Histamine and 5-Hydroxy-Tryptamine (Serotonin) and Their Antagonists," Goodman & Gilman's The Pharmacological Basis of Therapeutics, 7th Ed., McMillan Publishing (1985).
O'Laughlin et al.: "Healing of Aspirin-Associated Peptic Ulcer Disease Despite Continued Colicilate Injection", Archives of Internal Medicine, 141:781-783 (1981).
(3 pages)
Weserstein, M. et al.: "In Vivo Evaluation of the Effect of Antacids and H2 Blockers and Intragastric pH in the Gastric and Duodeanl Ulser," Acta Gastroenterol. Latinoam, 15(4):243-256 (1985).
Histamine H2 -Receptor Antagonists Systemic, USP DI Review Page, 1-24 (Jun. 17, 1992).
Frislid, K. et al.: Br Med J, 286:1358 (1983).
(1 pages)
S. van Avermaet et al.: Gastroenterology, 102 (4) Part II, A184 Abstracts (1992).
Drug Evaluation Monographs, Micromedex, Inc. 76 Exp. (May 31, 1993).
Drug Evaluation Monographs, Micromedex, Inc., 76 Exp. (May 31, 1993).
Drug Consults, Micromedex, Inc., 76 Exp. (May 31, 1993).
Drug Interaction Facts, Facts and Comparisons, 338 (Apr., 1991).
Drug Interaction Facts, Facts and Comparisons, 187 (Jul., 1991).
Lin, H. F.: Clin. Pharmacokinet., 20(3):218-236 (1991).
(19 pages)
[ISI abstract]
Desager, J. P. et al.: J. International Medical Research, 17:62-67 (1989).
(6 pages)
Drug Interaction Facts, Facts and Comparisons, 612 (Jul., 1990).
Stockley, I. H.: Drug Ineractions, A Source Book of Adverse Interactions, Their Mechanisms, Clinical Importance and Management, 2nd Ed., Blackwell Scientific Publicaitons 614-615 (1991).
Shelly, D. W. et al.: Drug Intell. Clin. Pharm., 20:792-795 (Oct., 1986).
(4 pages)
Albin, H. et al.: Eur. J. Clin. Pharmacol., 32:97-99 (1987).
(3 pages)
D'Arcy, P. F. et al.: Drug Intell. Clin. Pharm., 21:607-617 (1987).
(11 pages)
Donn, K. H. et al.: Pharmacotherapy, 4:89-92 (1984).
(4 pages)
Hansten, P. D. et al.: Drugs Interactions Newsletter, 5(3):11-14 (Mar., 1985).
Gannoulis, N. et al.: Gastroenterology, 90:A1393 (May, 1986).
(1 pages)
Albin, H. et al.: Eur. J. Clin. Pharmacol., 26:271-273 (1984).
(3 pages)
Russell, W. L. et al.: Digestive Diseases and Sciences, 29(5):385-389 (May, 1984).
(5 pages)
Mahachai, V. et al.: Clinical Therapeutics, 6(6):808-823 (1984).
(16 pages)
Steinberg, W. M. et al.: Gastroenterology, 78:A1269 (May, 1980).
(1 pages)
Gugler, R. et al.: Eur. J. Clin. Pharmacol., 20:225-228 (1981).
(4 pages)
Gugler, R. et al.: Clin. Pharmacol. Ther., 29(6):744-748 (Jun., 1981).
(5 pages)
Bodemar, G. et al.: Br. Soc. Gastroenterology, 19:A990 (1979).
Bodemar, G. et al.: Lancet (Letter), 444-445 (Feb. 24, 1979).
(2 pages)
Ganjian, F. et al.: J. Pharm. Sci., 69(3):352-353 (Mar., 1980).
(2 pages)
Burland, W. L. et al.: Lancet, (Letter) 965 (Oct. 30, 1976).
(1 pages)
Longstreth, G. F. et al.: Gastroenterology, 72(1):9-13 (1977).
(5 pages)
Clayman, C. B.: JAMA, 238(12):1289-1290 (Sep. 19, 1977).
(2 pages)
Lin, J. H. et al.: Br. J. Clin. Pharmac., 24:551-553 (1987).
(3 pages)
Gallaghan, J. T. et al.: Scanned J. Gastroenterol., 22(Suppl 136):9-17 (1987).
Barzaghi, N. et al.: Eur. J. Clin. Pharmacol., 37:409-410 (1989).
(2 pages)
|
|
 Nominate this for the Gallery...
|
|
